LEANer Trial Reveals Limitations of Unsupervised Lifestyle Interventions During Breast Cancer Chemotherapy

What Does the LEANer Trial Tell Us About Lifestyle Interventions?

The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) trial has provided valuable insights into the effects of a combined nutrition and exercise intervention on quality of life for women undergoing breast cancer chemotherapy. This yearlong intervention, which included comprehensive nutrition and exercise counseling delivered by registered dietitians with specialized oncology training, was compared to usual care in 173 women newly diagnosed with stage I-III breast cancer. While the intervention successfully improved health behaviors, the secondary analysis revealed no significant differences in patient-reported quality of life outcomes between the intervention and usual care groups, raising important questions about intervention design and delivery during active cancer treatment.

How Do Quality of Life Measures Evolve During Breast Cancer Treatment?

At baseline, women in both study arms exhibited higher anxiety levels (54.9) and better social roles (55.0) compared to the general population. During chemotherapy, participants in both groups experienced clinically meaningful declines in physical function, increased fatigue, decreased social roles, and worsening cognitive function. Global physical and mental health measures also showed substantial deterioration immediately following chemotherapy. Interestingly, anxiety improved in both groups from baseline to post-chemotherapy and remained better than baseline through the two-year follow-up, potentially reflecting the resolution of anticipatory anxiety once treatment was underway. Most quality of life measures returned to baseline levels by one year post-randomization and remained stable through the two-year assessment, suggesting the transient nature of many chemotherapy-related symptoms.

Could Revised Intervention Strategies Enhance Patient Outcomes?

Despite the intervention's success in increasing physical activity (with a mean difference of 97.6 minutes per week at post-chemotherapy and 136.1 minutes per week at one year compared to usual care) and improving diet quality, these behavioral changes did not translate to measurable differences in quality of life as assessed by PROMIS measures. Several factors may explain these findings. The intervention was home-based and unsupervised, with counseling provided through weekly calls from dietitians. Previous research suggests that supervised exercise programs may have greater impact on quality of life outcomes than unsupervised approaches. Additionally, the intensity of the intervention may not have been sufficient to influence quality of life metrics during the particularly challenging period of active chemotherapy. The PROMIS instruments themselves may also lack sensitivity to detect smaller yet clinically relevant changes during cancer treatment.

The LEANer intervention was based on a Social Cognitive Theory framework and adapted from the Diabetes Prevention Program, with modifications specifically addressing active cancer treatment challenges. Participants received 16 thirty-minute counseling sessions over one year, with gradually decreasing frequency (weekly sessions in the first month, biweekly for months 2-3, and monthly thereafter). The exercise goal was to progressively reach 150 minutes per week of moderate-intensity physical activity plus twice-weekly strength training, aligning with established guidelines from the American Cancer Society and American College of Sports Medicine. The nutrition component emphasized a predominantly plant-based diet following the Dietary Guidelines for Americans and cancer survivorship recommendations. Despite high adherence to the intervention sessions (90% of women attended at least 80% of scheduled sessions), and significant improvements in both exercise minutes and diet quality compared to usual care, these behavioral changes did not translate to between-group differences in quality of life outcomes.

Do Patient Characteristics and Lifestyle Behaviors Predict Quality of Life Improvements?

Exploratory analyses revealed important demographic and clinical factors associated with quality of life changes. Women with less education experienced greater worsening in fatigue during chemotherapy compared to those with higher education, highlighting potential socioeconomic disparities in treatment experiences. Neoadjuvant chemotherapy was associated with worse physical and mental health outcomes compared to adjuvant chemotherapy, possibly because these patients were still anticipating surgery at the time of assessment. Age also emerged as a significant modifier, with older women randomized to the intervention showing better recovery of mental health at one year compared to usual care, while younger women showed no intervention benefit. This age-related difference suggests the need for tailored approaches that specifically address the mental health needs of younger women with breast cancer.

The study found weak but statistically significant correlations between increases in exercise and improvements in social roles, anxiety, depression, and mental health, supporting the biological plausibility of exercise benefits during cancer treatment. Similarly, improvements in diet quality correlated with reductions in sleep disturbance. These correlations, while modest, suggest potential mechanistic pathways through which lifestyle interventions might influence specific quality of life domains, even if the overall intervention effect was not detected between study arms. The timing of assessments may have influenced the findings, as PROMIS measures were collected only at specific timepoints (post-chemotherapy, one year, and two years), potentially missing symptom fluctuations across individual chemotherapy cycles.

What Do Study Demographics Tell Us About Generalizability?

Of the 173 women randomized, retention remained relatively high throughout the study, with 157 (90.8%) completing PROMIS questionnaires at post-chemotherapy, 145 (83.8%) at one year, and 129 (74.6%) at two years. The study sample was predominantly non-Hispanic White (71%), with a mean age of 53 years and average BMI of 29.7 kg/m². Most participants had stage I breast cancer (51%), and 42% received neoadjuvant chemotherapy. This demographic composition limits the generalizability of findings to more diverse patient populations. The comprehensive assessment included multiple PROMIS domains, providing a holistic view of quality of life changes during and after treatment, though the study did not collect real-time use of anti-nausea or other supportive medications, which might have differed between groups and potentially contributed to the null findings.

How Might These Findings Shape Future Supportive Care?

This study contributes important evidence to the growing body of research on supportive interventions during breast cancer treatment. While guidelines already support exercise during cancer treatment to preserve physical function and reduce fatigue, anxiety, and depression, the role of nutrition interventions remains less clear. The LEANer trial's findings suggest that unsupervised, home-based nutrition and exercise interventions, despite improving health behaviors, may not be sufficient to mitigate quality of life declines during chemotherapy. Future research should explore more intensive or supervised intervention approaches, more frequent assessment of patient-reported outcomes, and strategies tailored to specific demographic subgroups, particularly younger women who may require additional mental health support during and after cancer treatment.

Could more frequent assessment of patient-reported outcomes throughout chemotherapy cycles provide a more nuanced understanding of intervention effects on symptom management? How might the intensity, supervision, and personalization of lifestyle interventions be optimized to better support quality of life during the particularly challenging period of active cancer treatment? What additional supportive care strategies might be needed to address the unique mental health needs of younger women undergoing breast cancer treatment? These questions highlight important directions for future research to enhance supportive care and quality of life for women with breast cancer.

Summary

The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) trial investigated the impact of a yearlong combined nutrition and exercise intervention on quality of life in 173 women newly diagnosed with stage I-III breast cancer undergoing chemotherapy. The intervention, delivered through weekly counseling sessions by specialized oncology dietitians, successfully improved health behaviors, with participants achieving 97.6 to 136.1 more minutes of physical activity per week and better diet quality compared to usual care. However, secondary analysis revealed no significant differences in patient-reported quality of life outcomes between groups as measured by PROMIS instruments. During chemotherapy, both groups experienced clinically meaningful declines in physical function, social roles, and cognitive function, along with increased fatigue, though most measures returned to baseline by one year post-randomization. Exploratory analyses identified important predictors of quality of life changes, including education level, chemotherapy timing, and age, with older women showing better mental health recovery with the intervention while younger women showed no benefit. The study suggests that unsupervised, home-based interventions may not be sufficient to mitigate quality of life declines during active chemotherapy, highlighting the need for more intensive or supervised approaches, particularly tailored to younger women who may require additional mental health support during cancer treatment.